Global Peptide Index
Get weekly changes

DATA STORY · TRIAL OUTCOMES

10.5% of peptide trials on ClinicalTrials.gov were stopped early

1,029 of 9,827 registered trials of the 60 peptides this index tracks were stopped before completion: 689 terminated, 318 withdrawn before enrolling anyone, 22 suspended. Of the 6,751 trials that have reached an end, 15.2% stopped early.

CHART

Share of trials stopped early, peptides with at least 50 registered trials

Share of trials stopped early, peptides with at least 50 registered trialsBacitracin30.2%Daptomycin27%Lanreotide17.9%Octreotide16%Carfilzomib15.5%Vancomycin14.7%Pramlintide14.1%Leuprolide13.7%Ciclosporin13.4%Goserelin12.3%Glutathione12.3%Angiotensin II11.9%
Bacitracin16 of 53
Daptomycin33 of 122
Lanreotide21 of 117
Octreotide52 of 325
Carfilzomib43 of 278
Vancomycin102 of 695
Pramlintide9 of 64
Leuprolide71 of 517
Ciclosporin175 of 1309
Goserelin51 of 415
Glutathione33 of 269
Angiotensin II42 of 354

Source: ClinicalTrials.gov, read 2026-09-04.

THE FIGURES

  • 9,827 registered trials, 60 peptides.
  • 5,722 completed.
  • 689 terminated, 318 withdrawn, 22 suspended.
  • Highest share stopped early, among peptides with at least 50 trials: Bacitracin, 16 of 53 (30.2%).

METHOD

Stopped early means the register status is TERMINATED, WITHDRAWN or SUSPENDED. A trial linked to two peptides counts once in the total and once for each peptide in the chart. Statuses are as the sponsor last reported them.

Free to quote and chart with a link to this page. Not medical, legal or regulatory advice.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.